The goal of the Biometry Core is to provide data management support for all projects, and to collaborate with project investigators in the development and application of statistical methods for design and analysis. This goal is achieved through the following specific aims: 1. To provide statistical design and review of clinical and laboratory studies including feasibility assessment and sample size estimation. 2. To develop procedures for data collection and to maintain computer databases for information storage and retrieval. 3. To provide statistical collaboration in the execution and analysis of all studies. 4. To interpret the statistical and biological literature relevant to all projects, and to develop new study design and data analysis procedures when required. Biometry support is required in all phases of the proposed studies. During study design the core will address statistical power and sample size issues, and will work with study investigators to establish data management procedures. Upon study completion, the core performs statistical analyses in collaboration with study I investigators. Core personnel will also prepare and assist in the preparation of manuscripts for publication. The Biometry Core continues to be used by all investigators in clinical and laboratory studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA090821-01
Application #
6494955
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-07-01
Project End
2006-12-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722
Stephen, Renu M; Pagel, Mark D; Brown, Kathy et al. (2012) Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Exp Biol Med (Maywood) 237:1273-80
Ihle, N T; Powis, G; Kopetz, S (2011) PI-3-Kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets 11:190-8
Ihle, Nathan T; Lemos Jr, Robert; Wipf, Peter et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-50
Baker, Amanda F; Koh, Mei Y; Williams, Ryan R et al. (2008) Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas 36:178-86
Koh, Mei Y; Spivak-Kroizman, Taly; Venturini, Sara et al. (2008) Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7:90-100
Bagatell, Rochelle; Gore, Lia; Egorin, Merrill J et al. (2007) Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783-8
Raghunand, Natarajan; Jagadish, Bhumasamudram; Trouard, Theodore P et al. (2006) Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med 55:1272-80
Williams, Ryan; Baker, Amanda F; Ihle, Nathan T et al. (2006) The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother Pharmacol 58:444-50
Powis, Garth; Wipf, Peter; Lynch, Stephen M et al. (2006) Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther 5:630-6
Baker, Amanda F; Dragovich, Tomislav; Tate, Wendy R et al. (2006) The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med 147:83-90

Showing the most recent 10 out of 26 publications